Mainz Biomed nearly doubles on mRNA biomarkers deal

Quantum Cyber NV

05/01/2022 12:36

** Shares of German molecular genetics firm  MYNZ.O  jump
92% premarket to $19.88 - set to open at highest since debuting
in November
    ** Says struck deal to exclusively access Socpra Sciences
Santé Et Humaines' portfolio of novel mRNA biomarkers to be used
with ColoAlert - co's detection test for colorectal cancer
 urn:newsml:reuters.com:*:nFWN2TL03H
    ** Shares of the cancer detection company set for best
session 
    ** Co to start clinical study in Europe to evaluate efficacy
of these biomarkers to enhance ColoAlert's utility, aiming to
make it the most accurate at-home test for colorectal cancer
    ** MYNZ among the "Trending Tickers https://stocktwits.com/symbol/MYNZ
" list on investor-focused social media site Stocktwits, with
message volumes more than doubling
    ** As of last close, MYNZ has fallen ~27% from opening price
of $14.35 on market debut
    

 (Reporting by Susan Mathew)
 ((susan.mathew@thomsonreuters.com))